Peer Review History
| Original SubmissionApril 23, 2020 |
|---|
|
PONE-D-20-11705 Lipopolysaccharide triggers different transcriptional signatures in taurine and indicine cattle macrophages: reactive oxygen species and potential outcomes to the development of immune response to infections PLOS ONE Dear Dr. Wanessa Araujo Carvalho, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. I asked 2 external reviewers to examine your submission and their comments are attached and their recommendations are somewhere between minor and major recommendations. One reviewer was an expert bioinformatician, while the other a specialist in bovine infections, so they raise different points that have to be addressed. Please submit your revised manuscript by Jul 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Gordon Langsley Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. In your Methods section, please state the volume of the blood samples collected for use in your study. 3. In your Methods section, please include a comment about the state of the animals following this research. Were they euthanized or housed for use in further research? If any animals were sacrificed by the authors, please include the method of euthanasia and describe any efforts that were undertaken to reduce animal suffering. 4. We note that you are reporting an analysis of a microarray, next-generation sequencing, or deep sequencing data set. PLOS requires that authors comply with field-specific standards for preparation, recording, and deposition of data in repositories appropriate to their field. Please upload these data to a stable, public repository (such as ArrayExpress, Gene Expression Omnibus (GEO), DNA Data Bank of Japan (DDBJ), NCBI GenBank, NCBI Sequence Read Archive, or EMBL Nucleotide Sequence Database (ENA)). In your revised cover letter, please provide the relevant accession numbers that may be used to access these data. For a full list of recommended repositories, see http://journals.plos.org/plosone/s/data-availability#loc-omics or http://journals.plos.org/plosone/s/data-availability#loc-sequencing. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: From indicine and taurine bovine blood samples, the authors induce macrophages from monocytes. The macrophages are then treated with (and without) lipopolysaccharide, followed by RNA-Seq. Using conventional software, differential genes are detected and compared between species and between treated and untreated samples. Further, RT-qPCR is performed for a selection of target genes. From this, the authors find distinct differences in the immune responses between indicine and taurine. The topic is timely and interesting findings are presented. I find it difficult to understand exactly how the RNA sequencing results and the qPCR validations relate to each other. Figure 6 shows a number of genes not appearing in Figure 3, suggesting to me that the authors are validating a set of genes based on their a priori knowledge, rather than confirming the results obtained from the RNA-Seq? This may of course not be a problem in itself as long as the authors clearly state and justify this. More importantly, assuming that the genes from Figure 6 are not hidden somewhere in Figure 3 (and just not mentioned by name), there should be a thorough comparison between the RNA-Seq and the qPCR results. Calling DGE genes is a fairly arbitrary process depending on the specific threshold levels applied, so it would be naive to expect an exact correspondence between DGE genes and qPCR results. But it is essential to know if these different experimental approaches are in direct contrast to each other. Besides this, the expression levels, fold-change and FDR values should be presented as supplementary material. In fairness, the authors state (line 465) that some findings are from "different experimental strategies". But this nevertheless gives the reader a sense of cherry picking results that fit conventional wisdom within the field. Figure 6: It is unclear to me why these genes are suddenly tested in duffy blood? Why not use the MDM results from FigS2? (line 374 in the main text refers to FigS2 as "RNA sequencing" but it appears to be RT-qPCR results as well, which is also stated in its legend). And why are the same genes not tested (or presented) for both duffy and MDM? Figure 3: It is not clear to me what the Z-scores reflect. Are they calculated between gir and holstein samples, or within each sample? Intuitively I would expect that green/positive scores meant up-regulated, but on line 508 it is stated that NOS2, C3, IL36β and CCL24 are generally up-regulated in gir. Yet, only CCL24 appears to be 'green' in gir (so behaving opposite of the 3 other genes in any case - does "Most of the DEGs for inflammatory response biological process" then mean 3 out of 4?). A clearer explanation of this figure - and the specific procedure behind it - should be provided. To my knowledge, the RNA input material does exceed the recommendations for the TruSeq kit used in the study, yet it would be comforting to know the level of sequence redundancy between reads, ensuring that read abundance is not affected by biases during the library build. The samtools and picard software suites have tools to mark duplicate reads. Table 1 shows that the similar sequencing efforts between samples result in roughly even numbers of detected transcripts. Importantly, this does not reveal if the samples are exhausted, i.e. if deeper sequencing would result in a significantly higher number of detected transcripts. To test if a plateau of detected transcripts is reached would require a downsizing of the read data and subsequent re-analysis of such subsets. As this study aims to characterize major/general differences between the species, such a test is most likely not essential in this case. Yet, it would suit the manuscript of the authors briefly acknowledged this issue. lines 330-2: "It is also worth noting that activation of neutrophil degranulation pathways was detected in both breeds (S2 and S3 Tables), however showing different significances (taurine P=6.69E-04; indicine P= 0.01) suggesting a differential role of these cells in the biological responses of these breeds." Without knowing exactly how these p-values are produced (they are likely dependent on values derived from the entire pool of genes and not just the subset of genes being tested), these relatively subtle differences cannot form the basis for such speculations on different biological. The manuscript will need a language revision. On the first page of the introduction I found the following examples: "which reflects in variable response" "related with" "stimulates 40 host cells as monocytes/macrophages" "biding" "not capable to reproduce" Reviewer #2: The study of Carvalho et al., investigates the differential responses of Hostein (bos Taurus) and Gir (bos indicus) monocytes derived macrophages (MDMs) stimulated with LPS. The authors used RNAseq approaches, all procedures and step of analysis are well documented. The results showed a breed difference, suggesting a possibly divergent macrophages polarization (like the M1/M2 balance, well described in human and mice). I found the results sound and worthy of publication. I have the following specific comments/questions for the authors. Major: _ 4 biological replicates per group were used for the RNAseq. Why not n=6/group like for some other analysis in the manuscript? _ The UMD3.1.S4 genome was published in 2014. A new assembly version is available since 2018, under the name ARS-UCD1.2. Why not using the most recent version? _ The foldChange (FC) values considered by the authors were equal or superior to 1. This is not very stringent. Publication commonly used FC cut-off >1.5 or 2. Is the analysis still robust with a higher cut-off? _ The numbers of biological replicates (n=X) is lacking in the legend of figures 4, 5, 6 and S2. _ line 195 “RPLO and Ubiquitin were selected as housekeeping genes”. To meet the MIQE guidelines and publish qPCR data, authors should use at least 3 housekeeping genes for all experiments, even though then have tested 4 or 5 before selecting 2. Please include another housekeeping gene. _ Can the authors comment on the inter-individual variability among Holstein and Gir. Is it equivalent? Is it possible to show individual data, and median +/- interquartile range on the figures.(FigS2 for instance) _ Figure 3: the color code Green/Red is not visible by color blind people. Blue/orange or Blue/red are common colorblind-friendly palette. _ Figure 5 is interesting but gene names are not readable. Can the authors add a table with the 70 genes which showed an unique direct interaction to key transcription factors, and highlight the 22 which are associated to mastitis resistance. _ Lines 330-332 and 494-496: The authors have seeing the neutrophil degranulation pathways in both breeds, with different significances. They concluded that neutrophil could play a differential role in Holstein and Gir. I do not agree with this conclusion. If the granuloctes pathway is significantly found in the two groups, a higher p-value in one group does not mean a higher implication of this pathway. The authors suggest a stronger role for neutrophils in Holstein (lines 494-495), but in the S2 and S3 Tables, more genes are present in the Gir RNAseq data (19 genes in the data set /480 genes in the pathway) than in Holstein’s (11/480). Minor: _ Data are not fully available because the authors are using them to work on another project and have to respect intellectual property restrictions. For the reviewing process, RNA sequence data are supposed to be available from GEO repository, but I could not find the number 147813 on the GEO website. https://www.ncbi.nlm.nih.gov/gds/?term=147813 _ The authors used alternatively three different names for the animals: bos Taurus/bos indicus; or taurine/indicine; or Holstein/Gir. I would suggest to use the same terminology in the manuscript. For instance the first time Holstein (Bos Taurus) and Gir (bos indicus); and then “Holstein” and “Gir” in the rest of the manuscript and for the figures. I have the feeling that taurine and indicine are less obvious for the general audience but I may be wrong. My point is please use the same terminology everywhere in the article. _ Line 195 “4 housekeeping genes”, but 5 are listed into brackets. Please correct. _ Quality of figure 2 should be improved (too many pixels). _ Figure 5: “ECM” is not defined in the legend. _ Figure S1: what is “MNP1” in orange in the CD14 histogram? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Tobias Mourier Reviewer #2: Yes: Aude Remot [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Lipopolysaccharide triggers different transcriptional signatures in taurine and indicine cattle macrophages: reactive oxygen species and potential outcomes to the development of immune response to infections PONE-D-20-11705R1 Dear Dr. Wanessa Araujo Carvalho, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Gordon Langsley Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: I thank the authors for the revised version of the manuscript and the new analysis. All my comments were addressed and I do not have any further question. I endorse the manuscript for publication. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: Aude Remot |
| Formally Accepted |
|
PONE-D-20-11705R1 Lipopolysaccharide triggers different transcriptional signatures in taurine and indicine cattle macrophages: reactive oxygen species and potential outcomes to the development of immune response to infections Dear Dr. Carvalho: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Gordon Langsley Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .